Public ownership evidence

Xilio Therapeutics, Inc. Common Stock (XLO) Ownership Disclosures

Read XLO insider transactions, institutional 13F filings and Congressional disclosures with report dates, public availability and original receipts.

As of 2026-10-10T12:08:28.848Z

Separate the three disclosure sources

Step 1 of 3

Recent Form 4 activity

Xilio Therapeutics, Inc. Common Stock: source evidence dated 2026-10-10T12:08:28.848Z.

Available
2026-10-02
Trade date
2026-10-01
Reporting owners
Houvras Yariv
Code
A
Shares
105,000
Reported value
Not reported
What you should see

The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.

Step 2 of 3

Is this an insider transaction, 13F holding, or Congressional event?

Each source has different dates and units. Raw ticker-matched receipts, including amendments, are not deduplicated current ownership totals.

SEC 0001193125-26-412466
What you should see

Follow the source receipt or manager/member profile. Avoid combining transaction value and 13F position value into an ownership percentage.

Step 3 of 3

Read XLO fundamentals

Follow the source receipt or manager/member profile. Avoid combining transaction value and 13F position value into an ownership percentage.

Read XLO fundamentals
What you should see

Keep reporting dates and units beside the answer, and inspect its original citations.

Recent Form 4 activity

See the complete recent form 4 activity

Scroll sideways to compare all columns. Select a heading to sort.

2026-10-022026-10-01Houvras YarivA105,000Not reported

90-day public availability window, up to 50 records.

Recent institutional filing receipts

These are raw ticker-matched positions in recent 13F receipts, including amendments. They are not deduplicated current ownership totals. Open the manager profile to inspect its effective filing book.

Scroll sideways to compare all columns. Select a heading to sort.

Stonepine Capital Management, LLC2026-06-302026-08-18225,994$2,165,023None
Frazier Life Sciences Management, L.P.2026-06-302026-08-15422,505$4,047,598None
Velan Capital Investment Management LP2026-06-302026-08-1514,285$136,850None
Stonepine Capital Management, LLC2026-06-302026-08-15225,994$2,165,023None
Sio Capital Management, LLC2026-06-302026-08-15152,464$1,460,605None
JONES FINANCIAL COMPANIES LLLP2026-06-302026-08-1529$262None
Bain Capital Life Sciences Investors, LLC2026-06-302026-08-15664,021$6,361,322None
ORBIMED ADVISORS LLC2026-06-302026-08-15592,300$5,674,234None
ADAGE CAPITAL PARTNERS GP, L.L.C.2026-06-302026-08-15111,541$1,068,563None
BRIDGEWAY CAPITAL MANAGEMENT, LLC2026-06-302026-08-1517,544$168,072None
CITADEL ADVISORS LLC2026-06-302026-08-1525,950$248,601None
PRELUDE CAPITAL MANAGEMENT, LLC2026-06-302026-08-1511,600$111,128None
TWO SIGMA INVESTMENTS, LP2026-06-302026-08-1514,544$139,332None
BARCLAYS PLC2026-06-302026-08-15115$1,102None
VANGUARD CAPITAL MANAGEMENT LLC2026-06-302026-08-14178,517$1,710,193None
Steward Partners Investment Advisory, LLC2026-06-302026-08-14714$6,840None
UBS Group AG2026-06-302026-08-1414$134None
RENAISSANCE TECHNOLOGIES LLC2026-06-302026-08-1464,153$614,586None
VANGUARD FIDUCIARY TRUST CO2026-06-302026-08-1422,594$216,451None
MORGAN STANLEY2026-06-302026-08-1456,954$545,619None
GEODE CAPITAL MANAGEMENT, LLC2026-06-302026-08-136,532$62,576None
GEODE CAPITAL MANAGEMENT, LLC2026-06-302026-08-1332,523$311,598None
BlackRock, Inc.2026-06-302026-08-088,219$78,738None
BlackRock, Inc.2026-06-302026-08-08538$5,154None
Merck & Co., Inc.2026-06-302026-08-08105,982$1,015,308None
STATE STREET CORP2026-06-302026-08-0813,311$127,519None
GSA CAPITAL PARTNERS LLP2026-06-302026-08-0713,590$130,000None
GILEAD SCIENCES, INC.2026-06-302026-08-04650,389$6,230,727None
Key Financial Inc2026-06-302026-07-2559$565None

90-day public filing window, up to 50 source positions.

Stonepine Capital Management, LLC ↗Frazier Life Sciences Management, L.P. ↗Velan Capital Investment Management LP ↗Stonepine Capital Management, LLC ↗Sio Capital Management, LLC ↗JONES FINANCIAL COMPANIES LLLP ↗Bain Capital Life Sciences Investors, LLC ↗ORBIMED ADVISORS LLC ↗ADAGE CAPITAL PARTNERS GP, L.L.C. ↗BRIDGEWAY CAPITAL MANAGEMENT, LLC ↗

Recent Congressional disclosures

No matching Congressional transactions were returned in this source preview.

Scroll sideways to compare all columns. Select a heading to sort.

No records are available for this view.

Bounded public source preview, up to 25 disclosed events.

How to read the disclosure dates

The tables report different things: insider transactions, institutional positions and Congressional transaction ranges. Read each table with its source dates and units. They cannot be added into a combined ownership percentage.

  1. Company insiders

    SEC Form 4 purchases, sales and awards report transactions and their public filing availability.

  2. Institutional managers

    13F reports disclose delayed quarter-end positions. They are not a record of trades between quarters.

  3. Congressional filers

    Periodic transaction reports disclose transaction dates and amount brackets. Public filing dates determine what researchers could know.

Institutional source directory ↗Congressional source directory ↗

Read the transaction codes

Awards use transaction code A, purchases P and sales S. An acquisition from an award is not the same as an open-market purchase. Joint filers may share a transaction. Use original receipts and availability dates to interpret the events.

Aurora · AI research assistant

Try this in Aurora

Edit the request, then open it in Aurora. You choose when to send it.